ECSP056016A - Nuevos derivados de 2-piridinacarboxamida - Google Patents

Nuevos derivados de 2-piridinacarboxamida

Info

Publication number
ECSP056016A
ECSP056016A EC2005006016A ECSP056016A ECSP056016A EC SP056016 A ECSP056016 A EC SP056016A EC 2005006016 A EC2005006016 A EC 2005006016A EC SP056016 A ECSP056016 A EC SP056016A EC SP056016 A ECSP056016 A EC SP056016A
Authority
EC
Ecuador
Prior art keywords
formula
atom
heteroaryl group
pyridinacarboxamida
membered heteroaryl
Prior art date
Application number
EC2005006016A
Other languages
English (en)
Inventor
Morihiro Mitsuya
Makoto Bamba
Fumiko Sakai
Hitomi Watanabe
Yasuhiro Sasaki
Teruyuki Nishimura
Jun-Ichi Eiki
Original Assignee
Banyu Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Banyu Pharma Co Ltd filed Critical Banyu Pharma Co Ltd
Publication of ECSP056016A publication Critical patent/ECSP056016A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a un compuesto que tiene un efecto activador de glucoquinasa y es útil como un agente terapéutico para diabetes mellitus, estando representado por la fórmula (I): [donde X1 representa un átomo nitrógeno, átomo azufre, átomo oxígeno o similares, R1 representa un grupo aril de 6- a 10- miembros, un grupo heteroaril de 5- a 7- miembros, o similares; D representa un átomo oxígeno o un átomo azufre, R2 y R3 son los mismos o diferentes, cada uno representando un átomo hidrógeno, grupo alquil inferior, o similares; una fórmula (II): representa un grupo heteroarilo de 5- a 7- miembros opcionalmente sustituido o similares; una fórmula (III): representa un grupo heteroarilo monocíclico o bicíclico] o una sal farmacéuticamente aceptable del mismo.
EC2005006016A 2003-02-13 2005-09-13 Nuevos derivados de 2-piridinacarboxamida ECSP056016A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003034987 2003-02-13
JP2003342860 2003-10-01
JP2004014799 2004-01-22

Publications (1)

Publication Number Publication Date
ECSP056016A true ECSP056016A (es) 2006-01-27

Family

ID=32995582

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2005006016A ECSP056016A (es) 2003-02-13 2005-09-13 Nuevos derivados de 2-piridinacarboxamida

Country Status (20)

Country Link
US (3) US7629362B2 (es)
EP (1) EP1598349B1 (es)
JP (1) JP4400563B2 (es)
KR (1) KR20050101208A (es)
AR (1) AR045414A1 (es)
AT (1) ATE517887T1 (es)
AU (2) AU2004220234C1 (es)
BR (1) BRPI0407283A (es)
CA (1) CA2515841C (es)
EC (1) ECSP056016A (es)
IL (1) IL169905A0 (es)
MA (1) MA27626A1 (es)
MX (1) MXPA05008619A (es)
NO (1) NO20054224L (es)
NZ (1) NZ540791A (es)
PE (1) PE20050194A1 (es)
TW (1) TWI336329B (es)
UA (1) UA82867C2 (es)
WO (1) WO2004081001A1 (es)
ZA (1) ZA200504852B (es)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7879840B2 (en) 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7393652B2 (en) 2000-05-10 2008-07-01 The Trustees Of Columbia University In The City Of New York Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2)
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7718644B2 (en) 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
JP2006509774A (ja) 2002-10-03 2006-03-23 ノバルティス アクチエンゲゼルシャフト ２型糖尿病の処置において有用なグルコキナーゼアクチベーターとしての置換（チアゾール−２−イル）−アミドまたはスルホンアミド
US7544678B2 (en) 2002-11-05 2009-06-09 The Trustees Of Columbia University In The City Of New York Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
GB0226930D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
UA82867C2 (en) 2003-02-13 2008-05-26 Banyu Pharma Co Ltd 2-pyridinecarboxamide derivatives
JP2007525165A (ja) 2003-03-07 2007-09-06 トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク タイプ１ライアノジン受容体に基づく方法
JP4707560B2 (ja) * 2003-12-29 2011-06-22 Ｍｓｄ株式会社 新規２−ヘテロアリール置換ベンズイミダゾール誘導体
US8710045B2 (en) 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
JP2007524682A (ja) * 2004-02-12 2007-08-30 メルク　エンド　カムパニー　インコーポレーテッド 代謝調節型グルタミン酸受容体−５の調節物質としてのビピリジルアミド
EP1737870A1 (en) 2004-04-02 2007-01-03 Novartis AG Thiazolopyridine derivates, pharmaceutical conditions containing them and methods of treating glucokinase mediated conditions
CN1960995B (zh) 2004-04-02 2010-12-08 诺瓦提斯公司 作为葡糖激酶活化剂、可用于治疗ⅱ型糖尿病的磺酰胺-噻唑并吡啶衍生物
EP1806337A4 (en) * 2004-10-08 2009-11-25 Banyu Pharma Co Ltd METHOD FOR THE SYNTHESIS OF A THIOETHER COMPOUND
BRPI0517232A (pt) 2004-11-02 2008-10-07 Banyu Pharma Co Ltd composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, ativador da glicocinase, e, agentes terapêuticos e/ou profiláticos para diabetes e para obesidade
EP1851202A1 (en) * 2005-02-25 2007-11-07 Takeda Pharmaceutical Company Limited Pyridyl acetic acid compounds
CN101133027B (zh) 2005-03-04 2011-03-30 弗·哈夫曼-拉罗切有限公司 作为mglur5拮抗剂的吡啶-2-甲酰胺衍生物
US7642259B2 (en) 2005-07-09 2010-01-05 Astrazeneca Ab Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
DE602006014001D1 (de) 2005-08-05 2010-06-10 Bristol Myers Squibb Co Herstellung von 2-aminothiazol-5-carbonsäurederivaten
US7704990B2 (en) 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
JP2009509988A (ja) 2005-09-29 2009-03-12 サノフィ−アベンティス フェニル−及びピリジニル−１，２，４−オキサジアゾロン誘導体、その製造方法、及び医薬品としてのその使用
GT200600428A (es) 2005-09-30 2007-05-21 Compuestos organicos
GT200600429A (es) 2005-09-30 2007-04-30 Compuestos organicos
AU2006295645B2 (en) * 2005-09-30 2011-09-29 Msd K.K. 2-heteroaryl-substituted indole derivative
ATE489386T1 (de) 2005-10-05 2010-12-15 Hoffmann La Roche Naphthyridin-derivate
NZ567858A (en) * 2005-11-01 2011-08-26 Array Biopharma Inc Pyridine compounds useful as Glucokinase activators
US8034822B2 (en) 2006-03-08 2011-10-11 Takeda San Diego, Inc. Glucokinase activators
CA2647208C (en) * 2006-03-24 2014-05-13 Array Biopharma Inc. Glucokinase activators
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
US8008332B2 (en) 2006-05-31 2011-08-30 Takeda San Diego, Inc. Substituted indazoles as glucokinase activators
CA2657566A1 (en) * 2006-07-24 2008-01-31 F. Hoffmann-La Roche Ag Pyrazoles as glucokinase activators
AR063028A1 (es) * 2006-10-06 2008-12-23 Banyu Pharma Co Ltd Derivados heterociclicos de piridin-2-carboxamida activadores de glucoquinasas, utiles para el tratamiento de diabetes y obesidad y composiciones farmaceuticas que los contienen.
AU2007307031B2 (en) * 2006-10-11 2011-11-24 Amgen Inc. Imidazo- and triazolo-pyridine compounds and methods of use therof
WO2008079787A2 (en) 2006-12-20 2008-07-03 Takeda San Diego, Inc. Glucokinase activators
WO2008084872A1 (ja) 2007-01-10 2008-07-17 Mitsubishi Tanabe Pharma Corporation ヒドラゾン誘導体
US8431713B2 (en) 2007-01-24 2013-04-30 Array Biopharma, Inc. 2-aminopyridine derivatives as glucokinase activators
US8173645B2 (en) 2007-03-21 2012-05-08 Takeda San Diego, Inc. Glucokinase activators
EP2173745A2 (en) * 2007-03-23 2010-04-14 Array Biopharma, Inc. 2-aminopyridine analogs as glucokinase activators
JP2010138073A (ja) * 2007-03-30 2010-06-24 Taisho Pharmaceutical Co Ltd ピコリン酸アミド化合物
WO2008156174A1 (ja) 2007-06-21 2008-12-24 Taisho Pharmaceutical Co., Ltd. ピラジンアミド化合物
EP2020232A1 (en) * 2007-08-03 2009-02-04 Zeltia, S.A. N-(1-thiazolyl)-amide derivatives for the treatment of obesity, diabetes and cardiovascular diseases
ES2393824T3 (es) * 2007-09-21 2012-12-28 Array Biopharma, Inc. Derivados de piridin-2-il-amino-1,2,4-tiadiazol como activadores de glucoquinasa para el tratamiento de diabetes mellitus
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
MX2010004673A (es) 2007-11-06 2010-05-27 Astrazeneca Ab Algunos derivados de 2-pirazinona y su uso como inhibidores de elastasa de los neutrofilos.
EP2221301B1 (en) 2007-11-12 2014-06-04 Msd K.K. Heteroaryloxy quinazoline derivative
CA2707403A1 (en) 2007-12-25 2009-07-02 Banyu Pharmaceutical Co., Ltd. N-pyrazole-2-pyridinecarboxamide derivative
WO2009083553A1 (en) * 2007-12-31 2009-07-09 Rheoscience A/S Azine compounds as glucokinase activators
CA2716385A1 (en) * 2008-02-27 2009-09-03 Lars Thore Burgdorf Carboxamide-heteroaryl derivatives for the treatment of diabetes
JP5498025B2 (ja) * 2008-03-13 2014-05-21 公益財団法人相模中央化学研究所 新規なチアゾール誘導体固定化マトリックス、及びその製造方法
WO2009113637A1 (ja) * 2008-03-12 2009-09-17 東ソー株式会社 新規なチアゾール誘導体、チアゾール誘導体固定化マトリックス、及びそれらの製造方法
JP5455380B2 (ja) * 2008-03-12 2014-03-26 公益財団法人相模中央化学研究所 新規なチアゾール誘導体、及びその製造方法
US8258134B2 (en) 2008-04-16 2012-09-04 Hoffmann-La Roche Inc. Pyridazinone glucokinase activators
US7741327B2 (en) 2008-04-16 2010-06-22 Hoffmann-La Roche Inc. Pyrrolidinone glucokinase activators
US8592428B2 (en) 2008-08-15 2013-11-26 Msd K. K. Acetyl pyrrolidinyl indole derivative
AU2009285194A1 (en) * 2008-08-29 2010-03-04 Banyu Pharmaceutical Co.,Ltd. Oxotetrahydrofuran-2-yl-benzimidazole derivative
GEP20135793B (en) 2008-09-11 2013-03-25 Pfizer Heteroaryls amide derivatives and their use as glucokinase activators
EP2358200A4 (en) 2008-11-17 2012-05-16 Merck Sharp & Dohme SUBSTITUTED BICYCLIC AMINES FOR THE TREATMENT OF DIABETES
TW201036957A (en) 2009-02-20 2010-10-16 Astrazeneca Ab Novel salt 628
DK2406253T3 (da) 2009-03-11 2013-08-12 Pfizer Benzofuranylderivater anvendt som glucokinase-inhibitorer
WO2011011506A1 (en) 2009-07-23 2011-01-27 Schering Corporation Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
CA2768577A1 (en) 2009-07-23 2011-01-27 Schering Corporation Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
US20110021570A1 (en) * 2009-07-23 2011-01-27 Nancy-Ellen Haynes Pyridone glucokinase activators
CA2771190C (en) 2009-08-17 2020-01-21 Memorial Sloan-Kettering Cancer Center Heat shock protein binding compounds, compositions, and methods for making and using same
JP5750050B2 (ja) * 2009-12-04 2015-07-15 大正製薬株式会社 ２−ピリドン化合物
US8222416B2 (en) * 2009-12-14 2012-07-17 Hoffmann-La Roche Inc. Azaindole glucokinase activators
US8178689B2 (en) 2010-06-17 2012-05-15 Hoffman-La Roche Inc. Tricyclic compounds
KR20140145624A (ko) 2012-04-16 2014-12-23 카네크 파마 인코포레이티드 Ptp-1b 억제제에 대한 전구체로서의 융합된 방향족 포스포네이트 유도체
EP2931718B1 (en) 2012-12-17 2019-01-16 Merck Sharp & Dohme Corp. Novel 2-pyridinecarboxamide derivatives, compositions containing such compounds, and methods of treatment
WO2015175707A1 (en) 2014-05-13 2015-11-19 Memorial Sloan Kettering Cancer Center Hsp70 modulators and methods for making and using the same
US20240067657A1 (en) * 2020-12-29 2024-02-29 Merck Sharp & Dohme Llc Amido-substituted pyridyl compounds and methods of use thereof for the treatment of herpesviruses
IL280384B (en) * 2021-01-25 2022-09-01 Ag Plenus Ltd Herbicidal compounds and methods of use thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3630200A (en) 1969-06-09 1971-12-28 Alza Corp Ocular insert
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
JPS56115784A (en) * 1980-02-15 1981-09-11 Tanabe Seiyaku Co Ltd Novel pyridinecarboxamide derivative and its preparation
JPS5795984A (en) 1980-12-05 1982-06-15 Tanabe Seiyaku Co Ltd Pyridinecarboxamide derivative and its preparation
JPS58121215A (ja) 1982-01-14 1983-07-19 Tanabe Seiyaku Co Ltd 抗アレルギ−剤
CH680582A5 (es) 1991-04-23 1992-09-30 Supermatic Kunststoff Ag
GB2277930A (en) 1993-05-11 1994-11-16 Shell Int Research Herbicidal picolinamide derivatives
US6022884A (en) 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
GB9725298D0 (en) 1997-11-28 1998-01-28 Zeneca Ltd Insecticidal thiazole derivatives
JP2002047278A (ja) 2000-08-02 2002-02-12 Fuji Photo Film Co Ltd チオエーテル化合物の製造方法
JP4723059B2 (ja) 2000-08-03 2011-07-13 帝人化成株式会社 難燃性熱可塑性樹脂組成物
SE0102300D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
SE519859C2 (sv) 2001-08-17 2003-04-15 Novacast Ab Anordning för behandling av järnlegeringar i ett kärl
AU2002952839A0 (en) * 2002-11-21 2002-12-05 Fujisawa Pharmaceutical Co., Ltd. Aminoalcohol derivatives
UA82867C2 (en) 2003-02-13 2008-05-26 Banyu Pharma Co Ltd 2-pyridinecarboxamide derivatives
WO2004076420A1 (ja) * 2003-02-26 2004-09-10 Banyu Pharmaceutical Co., Ltd. ヘテロアリールカルバモイルベンゼン誘導体
GB0327761D0 (en) 2003-11-29 2003-12-31 Astrazeneca Ab Compounds
ATE426597T1 (de) 2004-02-18 2009-04-15 Astrazeneca Ab Benzamidderivate und deren verwendung als glucokinaseaktivierende mittel
BRPI0507734A (pt) 2004-02-18 2007-07-10 Astrazeneca Ab composto ou um sal, pró-droga ou solvato do mesmo, método de tratar doenças mediadas por glk, e, processo para a preparação de um composto
EP1806337A4 (en) * 2004-10-08 2009-11-25 Banyu Pharma Co Ltd METHOD FOR THE SYNTHESIS OF A THIOETHER COMPOUND
AR063028A1 (es) * 2006-10-06 2008-12-23 Banyu Pharma Co Ltd Derivados heterociclicos de piridin-2-carboxamida activadores de glucoquinasas, utiles para el tratamiento de diabetes y obesidad y composiciones farmaceuticas que los contienen.
AR068540A1 (es) 2007-09-28 2009-11-18 Merck & Co Inc Metodos de produccion de un derivado de pirazol-3-il-benzamida.

Also Published As

Publication number Publication date
AU2010200004B2 (en) 2012-07-19
US7629362B2 (en) 2009-12-08
MA27626A1 (fr) 2005-11-01
KR20050101208A (ko) 2005-10-20
AU2004220234C1 (en) 2013-01-17
AU2004220234B2 (en) 2009-11-26
US8344003B2 (en) 2013-01-01
NZ540791A (en) 2009-09-25
AU2004220234A1 (en) 2004-09-23
CA2515841C (en) 2010-06-01
AR045414A1 (es) 2005-10-26
EP1598349A4 (en) 2008-12-31
AU2010200004A1 (en) 2010-01-28
NO20054224L (no) 2005-11-10
HK1088602A1 (zh) 2006-11-10
US20100041660A1 (en) 2010-02-18
JP4400563B2 (ja) 2010-01-20
EP1598349A1 (en) 2005-11-23
NO20054224D0 (no) 2005-09-12
ATE517887T1 (de) 2011-08-15
UA82867C2 (en) 2008-05-26
US8765789B2 (en) 2014-07-01
BRPI0407283A (pt) 2006-01-31
ZA200504852B (en) 2006-05-31
PE20050194A1 (es) 2005-04-23
TWI336329B (en) 2011-01-21
JPWO2004081001A1 (ja) 2006-06-08
US20060258701A1 (en) 2006-11-16
MXPA05008619A (es) 2005-11-04
TW200510381A (en) 2005-03-16
CA2515841A1 (en) 2004-09-23
IL169905A0 (en) 2007-07-04
US20130085156A1 (en) 2013-04-04
WO2004081001A1 (ja) 2004-09-23
EP1598349B1 (en) 2011-07-27

Similar Documents

Publication Publication Date Title
ECSP056016A (es) Nuevos derivados de 2-piridinacarboxamida
ES2594409T3 (es) Derivados de heteroarilo como moduladores del nAChR á7
ECSP099638A (es) Nuevo compuesto de adenina
ES2572148T3 (es) Un método para el tratamiento de la enfermedad de Pompe usando 1-desoxinojirimicina y derivados
AR040626A1 (es) Derivados de quinolina utiles como ligandos del receptor del neuropeptido y (npy)
NO20061107L (no) CRF-antagonister og heterobrcykliske forbindelser
ES2530943T3 (es) Derivados de la cromenona con actividad antitumoral
AR036659A1 (es) Compuestos derivados de fenil-piperazina, fenil-piperidina y fenil-tetrahidropiridina como inhibidores de la reabsorcion de la serotonina, una composicion farmaceutica y utilizacion de los mismos para la preparacion de medicamentos
NO20073729L (no) Heterocykliske forbindelser som CCR2B-antagonister
BRPI0407810A (pt) composto, composição farmacêutica, ativador da glicocinase, e, medicamento
CY1116885T1 (el) Υποκατεστημενα παραγωγα κυκλοεξυλομεθυλιου
AR051780A1 (es) Compuestos en anillo fusionados que contienen nitrogeno y utilizacion de los mismos
AR046831A1 (es) Compuestos de pirazolilo e imidazolilo biciclicos y usos de los mismos
CO5640104A2 (es) Derivados de aminoisoxazol activos como inhibidores de quinasa
CO5590895A2 (es) Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos
AR055563A1 (es) Compuestos de piridil acido acetico, agente farmaceutico y utilizacion del compuesto para preparar dicho agente
ES2476422T3 (es) Compuestos de piperidina 3,5-sustituida como inhibidores de renina
ECSP034707A (es) Derivados de urea como antagonistas de alfa integrado
NO20073811L (no) N-(heteroaryl)-1H-indol-2-karboksamidderivater og deres anvendelse som vanilloid TRPV1 reseptorligander
PE20091349A1 (es) Compuestos derivados de espiro 1,3,4-tiadiazol como inhibidores de la actividad quinesina ksp
AR094122A1 (es) Compuestos triciclicos moduladores de la actividad de cftr
AR063577A1 (es) Derivados 8- piperidinil - pirimido [1 2 a] pirimidin -6-ona y 8- piperidinil-2- pirimidinil- pirimido [1,2-a] pirimidin -6- ona sustituidos
AR094123A1 (es) Compuesto triciclicos
MXPA05013631A (es) Derivado heterociclico de metilsulfona.
BR0311960A (pt) Derivado de 1-[ (indol-3-il) carbonil] piperazina, uso do mesmo e composição farmacêutica